In her latest On target column published by the ESMO Daily Reporter, VHIO’s Elena Garralda discusses the expanding toolbox for immuno-oncology in advanced…
Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch
Published by ESMO’s Daily Reporter, Elena Garralda’s latest On target column explores the promise of neoadjuvant immunotherapy in the treatment…
The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
Developed by VHIO investigators, VIGex is a gene expression signature that classifies solid tumors into three categories based on the…
Published in the journal Clinical Cancer Research (1), preliminary results of a two-part, phase I first-in-human study show encouraging antitumor…
Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
In her latest On target column, author Elena Garralda, Executive Director of VHIO’s Research Unit for Molecular Therapy of Cancer…
Now published by the ESMO Daily Reporter (formerly by the ESMO Perspectives online magazine), the latest edition of On Target – Gathering…
